Induction of a distinct CD8 Tnc17 subset by transforming growth factor-β and interleukin-6

被引:89
作者
Liu, Shih-Jen
Tsai, Jy-Ping
Shen, Chia-Rui
Sher, Yuh-Pyng
Hsieh, Chia-Ling
Yeh, Yu-Ching
Chou, Ai-Hsiang
Chang, Shu-Rung
Hsiao, Kuang-Nan
Yu, Feng-Wei
Chen, Hsin-Wei
机构
[1] Natl Hlth Res Inst, Vaccine Res & Dev Ctr, Zhunan 350, Taiwan
[2] Chang Gung Univ, Grad Inst Med Biotechnol, Tao Yuan, Taiwan
[3] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan
[4] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan
关键词
IL-17; mixed lymphocyte culture; cytotoxic T lymphocyte;
D O I
10.1189/jlb.0207111
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cross-talk between TGF-beta and IL-6 has been shown to direct the differentiation of CD4(+) cells into special IL-17-secreting cells, which are termed Th17 cells. In this study, we demonstrated that TGF-beta and IL-6 could stimulate CD8(+) cells to differentiate into noncytotoxic, IL-17-producing cells in MLC. These IL-17-producing CD8(+) cells exhibit a unique granzyme B- IFN-gamma-IL-10-phenotype. The mRNA level of Th2/T cytotoxic 2 (Tc2) transcription factors GATA3 and Th1/Tc1 transcription factors T-box expressed in T cell (T-bet) as well as its target H2 center dot O-like homeobox (Hlx) is decreased in CD8(+) cells from TGF-beta and IL-6-treated MLC. In addition, these CD8(+) cells display a marked up-regulation of retinoic acid-related orphan receptor-gamma t, a key IL-17 transcription factor. These results demonstrate that the existence of an IL-17producing CD8(+) subset belongs to neither the Tc1 nor the Tc2 subset and can be categorized as a T noncytotoxic 17 (Tnc17) subset.
引用
收藏
页码:354 / 360
页数:7
相关论文
共 47 条
[1]   Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism [J].
Benchetrit, F ;
Ciree, A ;
Vives, V ;
Warnier, G ;
Gey, A ;
Sautès-Fridman, C ;
Fossiez, F ;
Haicheur, N ;
Fridman, WH ;
Tartour, E .
BLOOD, 2002, 99 (06) :2114-2121
[2]   Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].
Bettelli, E ;
Carrier, YJ ;
Gao, WD ;
Korn, T ;
Strom, TB ;
Oukka, M ;
Weiner, HL ;
Kuchroo, VK .
NATURE, 2006, 441 (7090) :235-238
[3]  
CARTER LL, 1995, J IMMUNOL, V155, P1028
[4]   Type 1 and Type 2: A fundamental dichotomy for all T-cell subsets [J].
Carter, LL ;
Dutton, RW .
CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (03) :336-342
[5]   Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection [J].
Cerwenka, A ;
Morgan, TM ;
Harmsen, AG ;
Dutton, RW .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (02) :423-434
[6]  
Cerwenka A, 1998, J IMMUNOL, V161, P97
[7]  
Chabaud M, 1998, J IMMUNOL, V161, P409
[8]   Liposome encapsulation of fluorescent nanoparticles: Quantum dots and silica nanoparticles [J].
Chen, Chien-Sheng ;
Yao, Jie ;
Durst, Richard A. .
JOURNAL OF NANOPARTICLE RESEARCH, 2006, 8 (06) :1033-1038
[9]   Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3 [J].
Chen, WJ ;
Jin, WW ;
Hardegen, N ;
Lei, KJ ;
Li, L ;
Marinos, N ;
McGrady, G ;
Wahl, SM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) :1875-1886
[10]   Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses [J].
Dobrzanski, MJ ;
Reome, JB ;
Hollenbaugh, JA ;
Dutton, RW .
JOURNAL OF IMMUNOLOGY, 2004, 172 (03) :1380-1390